OMG began as a medical cannabis company, leveraging the therapeutic potentials of cannabis for medical use. With meticulous research and a patient-centric product development, our rich history has set the foundation for our evolution as a biotech innovator.
As we transition to a biotech company, our core expertise now encapsulates:
Research is the heartbeat of OMG. With a culture that fosters innovation, our R&D focus seeks to uncover new pathways for treating diseases - we’re shaping the future of personalised medicine.
Our work has already resulted in a successful early-stage clinical trial for the symptoms of Type 2 diabetes. 71% of the participants reported significant improvement on their Type 2 diabetes markers including blood glucose.
Research and development and clinical trial preparation work has begun for our TGA Schedule 3 drug registration targeting sleep disorders. This includes our pharmacokinetic study and a large pivotal, international efficacy trial using our innovative, convenient oral sublingual tablet achieving more rapid onset when needed.
Based on extremely positive patient feedback OMG will commence an open label observational study in inflammatory arthritis targeting improved pain and function.
We operate at the highest level of integrity and compliance, meeting all regulatory standards to ensure that our products are not only innovative but also safe and effective.
Recognizing the power of collaboration, we partner with leading academic institutions, research centers, and industry giants to amplify our impact.
We are committed to being a driving force in the biotech industry, continuously seeking out opportunities for growth and innovation.
Join us on our journey to transform the landscape of advance biotechnological applications for medicinal cannabis. For collaborations, inquiries, or more information, contact us at Info@ozmedicann.com
Copyright © OZ Medicann Group Pty Ltd. Australia - 2024. Privacy Policy